Affiliation:
1. Centre of Personified Oncology of the Academy of Sciences of the Republic of Bashkortostan
2. Bashkir State Medical University; Centre of Personified Oncology of the Academy of Sciences of the Republic of Bashkortostan
3. Bashkir State Medical University
Abstract
Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.
Publisher
Bashkir State Medical University
Subject
General Engineering,Energy Engineering and Power Technology
Reference50 articles.
1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds). Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2020. 252 p.
2. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40. DOI: 10.1038/nrd2781
3. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297–309. DOI: 10.1038/nrc1588
4. Pipex pharmaceuticals announces presentation of phase I/II clinical trial results of COPREXA (Oral Tetrathiomolybdate) for the Treatment of Refractory Idiopathic Pulmonary Fibrosis (IPF) [cited 2021 Mar 17]. Available from: https://pipelinereview.com/index.php/2007052612034/Small-Molecules/Pipex-Pharmaceuticals-Announces-Presentation-of-Phase-I/II-Clinical-Trial-Results-of-COPREXA-Oral-Tetrathiomolybdate-for-the-Treatment-of-Refractory-Idiopathic-Pulmonary.html
5. Dudnyk V.M., Moroz L.V., Zaichko N.V., Kutsak O.V. Content of interleukins-4, 6 and nuclear transcription factor NF-κB in children with atopic bronchial asthma depending on ILE50Val polymorphism of IL4RA gene, severity of the disease course and level of its control. Zaporozhye Medical Journal. 2019;21(1):72–7 (In Russ.). DOI: 10.14739/2310-1210.2019.1.155818